Moderna raises 2026 outlook — Moderna (MRNA) earnings Q3 2026Skip NavigationMarketsPre-MarketsU.S.

Key Developments and Main Event

MarketsEurope MarketsChina MarketsAsia MarketsWorld MarketsCurrenciesPrediction MarketsCryptocurrencyFutures & CommoditiesBondsFunds & ETFsBusinessEconomyFinanceHealth & ScienceMediaReal EstateEnergyClimateTransportationInvestigationsIndustrialsRetailWealthSportsLifeSmall BusinessInvestingPersonal FinanceFintechFinancial AdvisorsOptions ActionETF StreetBuffett ArchiveEarningsTrader TalkTechCybersecurityAIEnterpriseInternetMediaMobileSocial MediaCNBC Disruptor 50Tech GuidePolitics & PolicyWhite HousePolicyDefenseCongressExpanding OpportunityEurope PoliticsChina PoliticsAsia PoliticsWorld PoliticsVideoLatest VideoFull EpisodesLivestreamTop VideoLive AudioEurope TVAsia TVCNBC PodcastsCEO InterviewsDigital OriginalsWatchlistInvesting ClubTrust PortfolioAnalysisTrade AlertsMeeting VideosHomestretchJim's ColumnsEducationSubscribePROPro NewsJosh BrownMike SantoliCalls of the DayMy PortfolioLivestreamFull EpisodesStock ScreenerMarket ForecastOptions InvestingChart InvestingSubscribeLivestreamMenuMake ItselectUSAINTLLivestreamSearch quotes, news & videosLivestreamWatchlistSIGN INCreate free accountMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting ClubPROLivestreamMenuHealth and ScienceModerna raises 2026 outlook as CEO says newer vaccines are gaining tractionPublished Fri, Nov 6 20266:47 AM ESTUpdated Fri, Nov 6 20267:43 AM ESTAnnika Kim Constantino@annikakimcWATCH LIVEKey PointsModerna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth.

The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. In an interview, Moderna CEO Stéphane Bancel pointed to new product launches and the "diversification" of geographies.

Core Facts and Essential Highlights

In this articleMRNAFollow your favorite stocksCREATE FREE ACCOUNTwatch nowVIDEO8:0208:02Moderna CEO Stephane Bancel on Q3 results: A big year of growth for usSquawk BoxModerna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum and Covid vaccine revenue outperforms.

Shares of Moderna rose roughly 3% in premarket trading on Friday. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. "The new product and the diversification of geography is what has led to such a strong Q3," Moderna CEO Stéphane Bancel said in an interview ahead of the results.

Broader Context and Market Implications

The Moderna facility in Laval, Quebec, Canada, Sept. 19, 2025.Graham Hughes | Bloomberg | Getty ImagesFor example, he said the company is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025.

Bancel noted that Covid is a seasonal business and vaccine contracts are typically established in the first quarter, so Moderna's shot only had a "small launch" to start with last year. Moderna's new stand-alone flu shot, which was approved in the U.S. in August, will similarly have a "limited launch" in the country in 2026 given the timing, he said.

In a separate interview on CNBC's "Squawk Box," Bancel said Moderna's geographic expansion in Canada, the U.K. and Asia helped boost results. The company's work to lower costs also resulted in a profit in the quarter, he added. "It's the sales that are stronger and the costs that are also lower," Bancel said.

Here's what Moderna reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:Earnings per share: 38 cents per share vs. an expected loss of $1.25Revenue: $1.31 billion vs.

$885.1 million expectedModerna's third-quarter revenue jumped 29% to $1.31 billion, boosted by higher Covid vaccine sales in international markets and helped by deliveries under long-term government partnerships. Revenue was $780 million in the U.S. and $533 million in international markets.

The company posted a net income of $162 million, or 38 cents per share, for the third quarter.